Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401884 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL1934654 | 0.89 | ADORA3 (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL10776201 | 0.85 | ADORA3 (0.49) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL31547787 | 0.84 | ADORA3 (0.44) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL6513941 | 0.83 | ADORA3 (0.48) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL6513952 | 0.83 | ADORA3 (0.48) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL30223675 | 0.83 | ADORA3 (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL22360999 | 0.83 | ADORA3 (0.56) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL27356878 | 0.83 | ADORA3 (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL8003530 | 0.83 | ADORA3 (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381102-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | CRESCITA THERAPEUTICS INC. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-4676241-A1 | COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | Axcess Global Sciences, LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4642475-A2 | ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTION | Tenza, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4585264-A2 | HUMAN CGRP RECEPTOR BINDING PROTEINS | AMGEN INC. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025123127-A1 | TOPICAL COMPOSITION AND USE THEREOF TO REDUCE POST-SURGICAL USE OF OPIOIDS | KAZM PHARMACEUTICALS INC. (CA) | 2025-06-19 | — | — | WO | disclosed |
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| EP-3569620-B1 | HUMAN CGRP RECEPTOR BINDING ANTIBODIES | AMGEN INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129172-A1 | HUMAN CGRP RECEPTOR BINDING PROTEINS | AMGEN INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4536209-A2 | CONJUGATE FOR TARGETING CENTRAL NERVOUS SYSTEM | Suntec Medical, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-0737201-A4 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND SOLID PHASE SYNTHESIS THEREOF | ISIS PHARMACEUTICALS INC (US) | 1998-12-30 | — | — | EP | disclosed |
| CN-1164259-A | Microbiological test method and reagent | SECR DEFENCE BRIT (GB) | 1997-11-05 | — | — | CN | disclosed |
| EP-0737201-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND SOLID PHASE SYNTHESIS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5536823-A | 3'-sulfonyl nucleoside compounds | INDIANA UNIVERSITY FOUNDATION (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995018136-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND SOLID PHASE SYNTHESIS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0334361-B1 | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | MERRELL DOW PHARMA (US) | 1995-04-19 | — | — | EP | disclosed |
| CN-1023804-C | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | MERRELL DOW PHARMA (US) | 1994-02-16 | — | — | CN | disclosed |
| US-4996308-A | Viricides, antitumor agent | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-02-26 | — | — | US | disclosed |
| CN-1036579-A | Novel acetylenic, cyano group and allenic aristeromycin element/adenosine derivative | MERRELL DOW PHARMA (US) | 1989-10-25 | — | — | CN | disclosed |
| EP-0334361-A2 | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381102-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | PLOD3, DSG1, POLR1C | ADORA3 4193/4885ADORA2A 3153/4885PI4KA 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.